Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Inclusion Criteria:

• >18 years old
• Karnofsky performance status > 60
• confirmed hematological malignancy
• refractory to available therapy or for which no therapy is available
• adequate hepatic, renal and hematological function

Exclusion Criteria:

• CNS malignancy
• at risk for prolonged QT interval
• significant GI/liver disease
• other serious concurrent illness or medical condition